Company Interview / The latest Aussie founded med-tech to hit the boards

Key points:

Saluda Medical (ASX:SLD) completed a $231 million IPO at $2.65 per shareTechnology offers clinically proven reduction in chronic pain and opioid usageMajority of raised funds will expand US commercial footprintGlobal operations with strong Australian roots and growing revenue forecast

Saluda Medical (ASX:SLD) has debuted on the ASX after raising $231 million in its IPO, issuing shares at $2.65 and reaching a market capitalisation of $775 million. Barry Regan highlights Saluda Medical's commercial focus on developing treatments for chronic neurological conditions. The company reaffirms its 2026 revenue guidance of nearly $82 million USD and boasts a global footprint, with 280 issued patents and active operations across the US, Europe, and Australia.

Regan points to the effectiveness of Saluda Medical’s technology, specifically its evoked spinal cord stimulation device, which applies electricity to the spine to counteract chronic pain signals. Clinical data collected over a three-year study indicates that 83% of patients experienced over 50% pain reduction, while 59% saw reductions above 80%. Additionally, 55% of patients reduced or eliminated opioid use after 12 months with the technology. Regan states this positions Saluda Medical with a strong clinical and commercial advantage.

With most of the capital raised set to expand the US sales force, Regan sees significant growth potential. Saluda currently accesses only 30% of US territories, aiming to double its sales force in the coming year to drive higher adoption among clinicians and patients.